Dr Sofia Merajver, MS, MD, PhD ☮️

Physician scientist at the University of Michigan. Opinions are my own. Professor of Internal Medicine and Epidemiology. she/her/hers

[Dr Sofia Merajver, MS, MD, PhD ☮️ @sofiamerajver]

@NarjustFlorezMD @YoungLungCancer @lcrf_org @LUNGevity @Florez_Lab Congratulations on this important study Narjust.

[OncLive.com @OncLive]

LISTEN 🎧: In our latest episode of #HowThisIsBuildingMe, @DRCamidge and @sofiamerajver discuss her lifelong journey shaped by immigration, intellectual curiosity, and a commitment to science in service of human health. #oncology

Click the link to hear her story 🔗▶️: https://t.co/oo9i2VWLze

[Oncogene Cancer Research @OncogeneCancer]

@YoungLungCancer @sofiamerajver Thank you Dr @sofiamerajver @UMRogelCancer for all you do for our lung cancer community and most of all your campassion and genuine interest in changing outcomes.

[Dr Sofia Merajver, MS, MD, PhD ☮️ @sofiamerajver]

Read my 5-star review of Spare These Stones: A Journey Through Southern Climbing Culture by Andrew Kornylak
If you ever climbed around trees and rocked as a child or ever, get to experience it again through these brilliant images and stories. https://t.co/XrJdgFLdeF

[Dr Sofia Merajver, MS, MD, PhD ☮️ @sofiamerajver]

Amazing but not enough! We want much more! Working on it every day is the only way. @UMRogelCancer so that’s what we do. Judith Tam ALK Kung Cancer Research Initiative https://t.co/j51vVxVy1n

[ALK Positive @ALKPositiveinc]

They’ve lived 10+ years with ALK-positive cancer.
That shouldn’t be rare—it should be the norm.

This #MakeAWillMonth, create a legacy that fuels research, hope & a future for all ALK+ patients.

Make your will free with @FreeWill ⬇️
👉 https://t.co/DBdzqr4jol

[ALK Positive @ALKPositiveinc]

They’ve lived 10+ years with ALK-positive cancer.
That shouldn’t be rare—it should be the norm.

This #MakeAWillMonth, create a legacy that fuels research, hope & a future for all ALK+ patients.

Make your will free with @FreeWill ⬇️
👉 https://t.co/DBdzqr4jol

[Dr Sofia Merajver, MS, MD, PhD ☮️ @sofiamerajver]

@ALKPositiveinc @wintrgrnbuffalo @Sunonmyhip @Yvonne_Diaz_ @oncodaily @OncogeneCancer @ALKPositiveAUS Onwards to more discoveries for patients’ lives

[ALK Positive @ALKPositiveinc]

Dr @sofiamerajver opens day 2 of the #ALKSummit25 discussing all of @UMRogelCancer’s increíble ALK+ cancer research.

Proud to have had a blood draw this year to advance this work. Our 2nd year running!

#StrongerTogether

[Dr Sofia Merajver, MS, MD, PhD ☮️ @sofiamerajver]

@MariosGeorgakis The kind of overblown title and claims that Cell gatekeepers love!!!

[Dr Sofia Merajver, MS, MD, PhD ☮️ @sofiamerajver]

@Yvonne_Diaz_ @ALKPositiveinc @OncogeneCancer @Janclarkgirls See you all soon!!! Cannot wait!!!

[Dr Sofia Merajver, MS, MD, PhD ☮️ @sofiamerajver]

@PitarresiLab What was the application topic or title? This is horrible. So sorry…

[Dr Sofia Merajver, MS, MD, PhD ☮️ @sofiamerajver]

Real progress towards understanding the actual metastasis potential cells in ALK+ LC. DNA is only a surrogate. Only live cells can kill patients. Let’s understand them much better and what drives them and let’s kill them. @UMRogelCancer

[LUNGevity Foundation @LUNGevity]

Mesenchymal (vimentin+) circulating tumor cells (#CTCs) may be progostic for progression in ALK+ #NSCLC. Great to see more non-invasive tests for progression. Collaboration between @NagrathSunitha Dr. Yuru Chen & Dr. Angel Qin @UMRogelCancer #AACR25 @ALKPositiveinc

[ALK+ International @ALKpositiveINT]

@FT3Program Too many to mention here but a few: @LUNGevity @sofiamerajver @JessicaJLinMD @Sdt36Suzanne @DrSanjayPopat @AngelQinMD @CUAnschutz @ICR_London @acmoorephd @StephenVLiu @JackWestMD @BairdAM @ChiFuJeffYang @SchenkLab @bencreelan @vincentlamMD @DCarboneMD @tnewsomdavis @DrRiyazShah

[Yvonne Diaz @Yvonne_Diaz_]

@ALKPositiveinc This is a truly exciting potential option for ALK once other options exhausted. Love the aim of repurposing drugs which can help get patients the treatments they need faster.

[ALK Positive @ALKPositiveinc]

What if a leukemia drug could help treat ALK+ lung cancer?

A new trial at @UMRogelCancerCtr is exploring gilteritinib—FDA-approved for leukemia—as a way to overcome resistance in ALK+ NSCLC.

🔗 Read the story: https://t.co/CbZtryKuOb
#DrugRepurposing #ALKPositive

[Dr Sofia Merajver, MS, MD, PhD ☮️ @sofiamerajver]

@motherofswans @MdBatra @UMRogelCancer We’ll work on that next… using similar advanced med chem principles. our precision medicine platform can analyze which drugs kill what fraction of each patient’s tumor right now! To life!

[Dr Sofia Merajver, MS, MD, PhD ☮️ @sofiamerajver]

We still use some of the same drugs my Dad got when I was 15. They are good drugs for other cancers but nor great on lung cancer. We r inventing new drugs, 2b reported soon. #moreresearchmorelife
#lcam @UMRogelCancer We want cures! Total elimination or minimal disease

[ALK Positive @ALKPositiveinc]

The quest for cancer cures is personal. Like for Dr @sofiamerajver who lost her dad to cancer when she was 15.

Its why Dr. Merajver is dedicated to increasing the quality & length of life for ALK+ #lungcancer patients & effecting real cures.

#MoreResearchMoreLife #LCAM

[ALK Positive @ALKPositiveinc]

The quest for cancer cures is personal. Like for Dr @sofiamerajver who lost her dad to cancer when she was 15.

Its why Dr. Merajver is dedicated to increasing the quality & length of life for ALK+ #lungcancer patients & effecting real cures.

#MoreResearchMoreLife #LCAM

[Caleb Cheng @DJCalebC]

Thank you!! Working hard every day to further improve on this work @LyssiotisLab @ArulChinnaiyan

[Dr Sofia Merajver, MS, MD, PhD ☮️ @sofiamerajver]

Good bye X. I try to do good and advance science to help humanity. This social platform is not where I can help the most. See you where it is 💙